SDC1 and neoplasm: Finally, immune cell-specific CD138 expression could be assessed in 151/154 (98.1 %) samples from primary tumours, in all 34 metastases and in 34/38 (89.5 %) samples from fallopian tubes, whereas tumour-specific expression of CD138 was quantifiable in 151 (98.1 %) of the primary tumours and in 30 (88.2 %) of the metastases.